Figure 1.
Workflow for NBN-targeted sequencing in pediatric patients with B-ALL. (A) CONSORT diagram of COG and St. Jude patients included in this study. (B) Protein domain plot of NBN (NM_002485): FHA, BRCT I and II, MRE11 and ATM interaction site (NBS1C), SP100 interaction site, and MTOR interaction site. The upper panel shows the amino acid substitutions predicted to result from the germ line NBN variants identified in this study. The numbers in circles indicate the number of patients that harbor the NBN variant of interest. BRCT, breast cancer C-terminus domain; FHA, forkhead-associated domain; MTOR, mechanistic target of rapamycin kinase; SNV, single nucleotide variant; SP100, SP100 nuclear antigen.

Workflow for NBN-targeted sequencing in pediatric patients with B-ALL. (A) CONSORT diagram of COG and St. Jude patients included in this study. (B) Protein domain plot of NBN (NM_002485): FHA, BRCT I and II, MRE11 and ATM interaction site (NBS1C), SP100 interaction site, and MTOR interaction site. The upper panel shows the amino acid substitutions predicted to result from the germ line NBN variants identified in this study. The numbers in circles indicate the number of patients that harbor the NBN variant of interest. BRCT, breast cancer C-terminus domain; FHA, forkhead-associated domain; MTOR, mechanistic target of rapamycin kinase; SNV, single nucleotide variant; SP100, SP100 nuclear antigen.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal